Evidence map›Paper›PMID 38346111›Full record

ArticleMedical physics2024

MRI-based prostate cancer classification using 3D efficient capsule network.

Yuheng Li, Jacob Wynne, Jing Wang, Justin Roper, Chih-Wei Chang, Ashish B Patel, Joseph Shelton, Tian Liu, Hui Mao, Xiaofeng Yang

Open access · greenAbstract read
In one paragraph

Article in Medical physics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yuheng LiDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Jacob WynneDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Jing WangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Justin RoperDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Chih-Wei ChangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Ashish B PatelDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Joseph SheltonDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Tian LiuDepartment of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Hui MaoThe Wallace H. Coulter Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, Georgia, USA.
Xiaofeng YangDepartment of Radiation Oncology and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Emory University · USThe Wallace H. Coulter Department of Biomedical Engineering · USIcahn School of Medicine at Mount Sinai · US

Funding

eXtended Modular ANthropomorphic (XMAN) phantom for Imaging and Treatment Optimization in Radiotherapy.R01EB032680 · NIBIB · UNIVERSITY OF MARYLAND BALTIMORE · PI REN, LEI, YANG, XIAOFENG · 2022 to 2025
$2.4M
Real-time Volumetric Imaging for Motion Management and Dose Delivery VerificationR01CA272991 · NCI · EMORY UNIVERSITY · PI Zhen Tian, Xiaofeng Yang · 2023 to 2026
$2.3M
Multiparametric MRI-guided Prostate HDR Brachytherapy with Focal Tumor BoostR01CA215718 · NCI · EMORY UNIVERSITY · PI YANG, XIAOFENG · 2018 to 2022
$1.8M
Artificial Intelligence Driven Platform for PET/MR ImagingR56EB033332 · NIBIB · EMORY UNIVERSITY · PI MAO, HUI, YANG, XIAOFENG · 2022 to 2022
$764k
NCI NIH HHS R01 CA215718NCI NIH HHS R01 CA272991NIBIB NIH HHS R01 EB032680NIBIB NIH HHS R56 EB033332NIH HHS R01CA215718NIH HHS R01EB032680NIH HHS R56EB033332
6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is the most common cancer in men and the second leading cause of male cancer-related death. Gleason score (GS) is the primary driver of PCa risk-stratification and medical decision-making, but can only be assessed at present via biopsy under anesthesia. Magnetic resonance imaging (MRI) is a promising non-invasive method to further characterize PCa, providing additional anatomical and functional information. Meanwhile, the diagnostic power of MRI is limited by qualitative or, at best, semi-quantitative interpretation criteria, leading to inter-reader variability. PURPOSES: Computer-aided diagnosis employing quantitative MRI analysis has yielded promising results in non-invasive prediction of GS. However, convolutional neural networks (CNNs) do not implicitly impose a frame of reference to the objects. Thus, CNNs do not encode the positional information properly, limiting method robustness against simple image variations such as flipping, scaling, or rotation. Capsule network (CapsNet) has been proposed to address this limitation and achieves promising results in this domain. In this study, we develop a 3D Efficient CapsNet to stratify GS-derived PCa risk using T2-weighted (T2W) MRI images.

methodsIn our method, we used 3D CNN modules to extract spatial features and primary capsule layers to encode vector features. We then propose to integrate fully-connected capsule layers (FC Caps) to create a deeper hierarchy for PCa grading prediction. FC Caps comprises a secondary capsule layer which routes active primary capsules and a final capsule layer which outputs PCa risk. To account for data imbalance, we propose a novel dynamic weighted margin loss. We evaluate our method on a public PCa T2W MRI dataset from the Cancer Imaging Archive containing data from 976 patients.

resultsTwo groups of experiments were performed: (1) we first identified high-risk disease by classifying low + medium risk versus high risk; (2) we then stratified disease in one-versus-one fashion: low versus high risk, medium versus high risk, and low versus medium risk. Five-fold cross validation was performed. Our model achieved an area under receiver operating characteristic curve (AUC) of 0.83 and 0.64 F1-score for low versus high grade, 0.79 AUC and 0.75 F1-score for low + medium versus high grade, 0.75 AUC and 0.69 F1-score for medium versus high grade and 0.59 AUC and 0.57 F1-score for low versus medium grade. Our method outperformed state-of-the-art radiomics-based classification and deep learning methods with the highest metrics for each experiment. Our divide-and-conquer strategy achieved weighted Cohen's Kappa score of 0.41, suggesting moderate agreement with ground truth PCa risks.

conclusionsIn this study, we proposed a novel 3D Efficient CapsNet for PCa risk stratification and demonstrated its feasibility. This developed tool provided a non-invasive approach to assess PCa risk from T2W MR images, which might have potential to personalize the treatment of PCa and reduce the number of unnecessary biopsies.

Indexed as

Magnetic Resonance ImagingNeural Networks, ComputerProstatic NeoplasmsHumansImaging, Three-DimensionalMaleMRIneural networkprostate cancerrisk classification

Identifiers

PMID38346111
PMCPMC12739645
OpenAlexW4391741843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.